InvestorsHub Logo
Followers 51
Posts 9165
Boards Moderated 1
Alias Born 10/25/2007

Re: trueblue post# 7863

Friday, 08/06/2021 12:53:36 AM

Friday, August 06, 2021 12:53:36 AM

Post# of 13551
Intratumoral Immuno-Oncology: These programs aim to drive anti-cancer T cell responses by injecting mRNA therapies directly into tumors.

OX40L/IL-23/IL-36? (Triplet) (mRNA-2752): The Phase 1 trial evaluating mRNA-2752 as a single agent and in combination with durvalumab in patients with advanced solid tumor malignancies and lymphoma is ongoing. Moderna owns worldwide commercial rights to mRNA-2752.

Actual Study Start Date : November 27, 2018
Estimated Primary Completion Date : July 31, 2021
Estimated Study Completion Date : July 31, 2021

at any moment NEWS!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News